Serina Therapeutics, Inc. (SER)
NYSEAMERICAN: SER · Real-Time Price · USD
3.150
+0.610 (24.02%)
Mar 23, 2026, 4:00 PM EDT - Market closed
Company Description
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain.
Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson’s disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles.
The company also develops SER 214 a POZ conjugate of rotigotine for the treatment of early Parkinson’s and Restless Leg Syndrome, which has completed phase 1a clinical trial.
In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases.
Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
Serina Therapeutics, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Nov 29, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Steven Ledger |
Contact Details
Address: 601 Genome Way, Suite 2001 Huntsville, Alabama 35806 United States | |
| Phone | 256 327 9630 |
| Website | serinatherapeutics.com |
Stock Details
| Ticker Symbol | SER |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001708599 |
| CUSIP Number | 81751A108 |
| ISIN Number | US81751A1088 |
| Employer ID | 82-1436829 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gregory S. Curhan | Chief Financial Officer |
| Dr. Srini Tenjarla | Senior Vice President of Chemistry, Manufacturing and Controls and Formulation |
| Dr. Randall W. Moreadith M.D., Ph.D. | Chief Development Officer |
| Dr. Joshua Thomas Ph.D. | Head of Chemistry |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 23, 2026 | 8-K | Current Report |
| Feb 13, 2026 | EFFECT | Notice of Effectiveness |
| Jan 30, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Jan 28, 2026 | 8-K | Current Report |
| Jan 20, 2026 | 144 | Filing |
| Jan 15, 2026 | 8-K | Current Report |
| Dec 10, 2025 | 8-K | Current Report |
| Nov 13, 2025 | 8-K | Current Report |
| Nov 13, 2025 | 10-Q | Quarterly Report |
| Nov 12, 2025 | 8-K | Current Report |